1,679
Views
49
CrossRef citations to date
0
Altmetric
Original Research

Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells

, , , , , , & show all
Article: e1036212 | Received 09 Feb 2015, Accepted 26 Mar 2015, Published online: 27 Jul 2015

References

  • Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60; PMID:17051156; http://dx.doi.org/10.1038/nature05236
  • Bensimon J, Altmeyer-Morel S, Benjelloun H, Chevillard S, Lebeau J. CD24(−/low) stem-like breast cancer marker defines the radiation-resistant cells involved in memorization and transmission of radiation-induced genomic instability. Oncogene 2013; 32:251-8; PMID:22330142; http://dx.doi.org/10.1038/onc.2012.31
  • Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PloS One 2011; 6:e20636; PMID:21695188; http://dx.doi.org/10.1371/journal.pone.0020636
  • Rasheed Z, Wang, Q, Matsui W. Isolation of stem cells from human pancreatic cancer xenografts. J Vis Exp 2010; 43:pii: 2169; PMID:20972397; http://dx.doi.org/10.3791/2169
  • Awad O, Yustein JT, Shah P, Gul N, Katuri V, O'Neill A, Kong Y, Brown ML, Toretsky JA, Loeb DM High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PloS One 2010; 5:e13943; PMID:21085683; http://dx.doi.org/10.1371/journal.pone.0013943
  • Lohberger B, Rinner B, Stuendl N, Absenger M, Liegl-Atzwanger B, Walzer SM, Windhager R, Leithner A. Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma. PloS One 2012; 7:e43664; PMID:22928012; http://dx.doi.org/10.1371/journal.pone.0043664
  • Honoki K, Fujii H, Kubo A, Kido A, Mori T, Tanaka Y, Tsujiuchi T. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol Rep 2010; 24: 501-5; PMID:20596639; http://dx.doi.org/10.3892/or_00000885
  • Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1:555-67; PMID:18371393; http://dx.doi.org/10.1016/j.stem.2007.08.014
  • Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011; 29:32-45; PMID:21280157; http://dx.doi.org/10.1002/stem.563
  • Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 2009; 13:2236-52; PMID:18681906; http://dx.doi.org/10.1111/j.1582-4934.2008.00455.x
  • Singh SKHawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004; 432:396-401; PMID:15549107; http://dx.doi.org/10.1038/nature03128
  • Canter RJ, Ames E, Mac S, Grossenbacher SK, Chen M, Li CS, Borys D, Smith RC, Tellez J, Sayers TJ et al. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. BMC Cancer 2014; 14:756; PMID:25301268; http://dx.doi.org/10.1186/1471-2407-14-756
  • Wang WJ, Wu SP, Liu JB, Shi YS, Huang X, Zhang QB, Yao KT. MYC Regulation of CHK1 and CHK2 Promotes Radioresistance in a Stem Cell-like Population of Nasopharyngeal Carcinoma Cells. Cancer Res 2013; 73(3):1219-31; PMID:23269272; http://dx.doi.org/10.1158/0008-5472
  • Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004; 104:2940-42; PMID:15251980; http://dx.doi.org/10.1182/blood-2004-04-1398
  • Barcellos-Hoff MH, Park C., & Wright E.G. Radiation and the microenvironment - tumorigenesis and therapy. Nat Rev. Cancer 2005; 5:867-75; PMID:16327765; http://dx.doi.org/10.1038/nrc1735
  • Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. J Clin Investig 2013; 123:2756-63; PMID:23863633; http://dx.doi.org/10.1172/JCI69219
  • Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366:925-31; PMID:22397654; http://dx.doi.org/10.1056/NEJMoa1112824
  • Hallett WH, Murphy WJ. Positive and negative regulation of Natural Killer cells: therapeutic implications. Semin Cancer Biol 2006; 16:367-82; PMID:16934486; http://dx.doi.org/10.1016/j.semcancer.2006.07.003
  • Perez-Cunningham J, Ames E, Smith RC, Peter AK, Naidu R, Nolta JA, Murphy WJ. Natural killer cell subsets differentially reject embryonic stem cells based on licensing. Transplantation 2014; 97:992-8; PMID:24704665; http://dx.doi.org/10.1097/TP.0000000000000063
  • Ames E, Murphy WJ. Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunol Immunother 2014; 63:21-8; PMID:23989217; http://dx.doi.org/10.1007/s00262-013-1469-8
  • Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9:503-10; PMID:18425107; http://dx.doi.org/10.1038/ni1582
  • Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol 2011; 89:216-24; PMID:20567250; http://dx.doi.org/10.1038/icb.2010.78
  • Xu Q, Liu G, Yuan X, Xu M, Wang H, Ji J, Konda B, Black KL, Yu JS. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 2009; 27:1734-40; PMID:19536809; http://dx.doi.org/10.1002/stem.102
  • Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, Mortini P, Ferrone S, Doglioni C, Marincola FM et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 2010; 16:800-13; PMID:20103663; http://dx.doi.org/10.1158/1078-0432.CCR-09-2730
  • Liao T, Kaufmann AM, Qian X, Sangvatanakul V, Chen C, Kube T, Zhang G, Albers AE. Susceptibility to cytotoxic T cell lysis of cancer stem cells derived from cervical and head and neck tumor cell lines. J Cancer Res Clin Oncol 2013; 139:159-170; PMID:23001491; http://dx.doi.org/10.1007/s00432-012-1311-2
  • Ishizawa K, Rasheed ZA, Karisch R, Wang Q, Kowalski J, Susky E, Pereira K, Karamboulas C, Moghal N, Rajeshkumar NV et al. Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 2010; 7:279-82; PMID:20804964; http://dx.doi.org/10.1016/j.stem.2010.08.009
  • Hwang-Verslues WW, Kuo WH, Chang PH, Pan CC, Wang HH, Tsai ST, Jeng YM, Shew JY, Kung JT, Chen CH et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PloS One 2009; 4:e8377; PMID:20027313; http://dx.doi.org/10.1371/journal.pone.0008377
  • Al-Hajj M, Wicha MS, Benito-Hernandez, A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983-88; PMID:12629218; http://dx.doi.org/10.1073/pnas.0530291100
  • Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M et al. Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 2015; 33(7):786-809; PMID:25605863; http://dx.doi.org/10.1200/JCO.2014.59.9746
  • Tallerico R, Todaro M, Di Franco S, Maccalli C, Garofalo C, Sottile R, Palmieri C, Tirinato L, Pangigadde PN, La Rocca R et al. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol 2013; 190:2381-90; PMID:23345327; http://dx.doi.org/10.4049/jimmunol.1201542
  • Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100:1935-47; PMID:12200350; http://dx.doi.org/10.1182/blood-2002-02-0350
  • Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013; 10:230-52; PMID:23604045; http://dx.doi.org/10.1038/cmi.2013.10
  • Wang B, Wang Q, Wang Z, Jiang J, Yu SC, Ping YF, Yang J, Xu SL, Ye XZ, Xu C et al. Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. Cancer Res 2014; 74:5746-57; PMID:25164008; http://dx.doi.org/10.1158/0008-5472.CAN-13-2563
  • Sungur CM, Tang-Feldman YJ, Zamora AE, Alvarez M, Pomeroy C, Murphy WJ. Murine NK-cell licensing is reflective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in murine cytomegalovirus responses. Blood 2013; 122:1518-21; PMID:23818546; http://dx.doi.org/10.1182/blood-2013-02-483503
  • Barao I, Alvarez M, Redelman D, Weiss JM, Ortaldo JR, Wiltrout RH, Murphy WJ. Hydrodynamic delivery of human IL-15 cDNA increases murine natural killer cell recovery after syngeneic bone marrow transplantation. Biol Blood Marrow Transplant 2011; 17:1754-64; PMID:21906575; http://dx.doi.org/10.1016/j.bbmt.2011.08.023

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.